Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Differential expression and prognostic role of selected genes in colorectal cancer patients

P. Pitule, O. Vycital, J. Bruha, P. Novak, P. Hosek, V. Treska, I. Hlavata, P. Soucek, M. Kralickova, V. Liska,

. 2013 ; 33 (11) : 4855-4865.

Language English Country Greece

Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't

Grant support
NT12025 MZ0 CEP Register
NT14329 MZ0 CEP Register

AIM: Colorectal cancer (CRC) is one of the most common malignant diseases. The aim of our study was to describe the expression status of 12 selected candidate genes, by comparing paired samples of healthy colon mucosa and tumour tissues and to correlate obtained data with clinical and pathological features, with the goal of revealing associations for individual gene expressions and tumour behaviour. MATERIALS AND METHODS: Samples from 53 patients with CRC were analyzed. Patients were divided into two groups based on the presence or absence of distant metastases at the time of primary tumour surgery. Expression levels were assessed by quantitative real-time polymerase chain reaction. RESULTS: We found changes in the expression of 10 out of 12 analyzed genes. Four genes were significantly up-regulated in tumour tissues: leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5; p<0.001), collagen triple helix repeat containing 1 (CTHRC1; p<0.001), visinin-like 1 (VSNL1; p<0.001) and versican (VCAN; p=0.001). Six genes were down-regulated: destrin (DSTN; p=0.004), mesoderm induction early response 1, family member 3 (MIER3; p<0.001), acyl-CoA synthetase long-chain family member 5 (ACSL5; p=0.002), mitogen-activated protein kinase 1/ERK (MAPK1; p<0.001), claudin 23 (CLDN23; p<0.001) and solute carrier family 26 (sulfate transporter), member 2 (SLC26A2; p<0.001). We recorded longer overall survival (OS) in the group of patients with higher expression of VSNL1 (p=0.032). Patients with more pronounced down-regulation of CLDN23 had shorter OS (p=0.045). In the group of patients without distant metastases, longer OS and disease-free interval (DFI) were found for patients with higher SLC26A2 expression in tumour tissues (p=0.036 and p=0.011, respectively). In the same group, lower expression of VSNL1 in healthy tissue corresponded to a longer DFI (p=0.020), smaller decrease of SLC26A2 and ACSL5 meant longer DFI (p=0.041 and p=0.040, respectively), as did greater increase of LGR5 expression (p=0.026). CONCLUSION: We identified differences in the expression of 10 genes in colorectal cancer tissue compared to healthy colon mucosa, and found prognostic significance for these changes which could be used for the development of a disease risk scoring system.

000      
00000naa a2200000 a 4500
001      
bmc14050754
003      
CZ-PrNML
005      
20190710101647.0
007      
ta
008      
140401s2013 gr f 000 0|eng||
009      
AR
035    __
$a (PubMed)24222123
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Pitule, Pavel $7 xx0170503
245    10
$a Differential expression and prognostic role of selected genes in colorectal cancer patients / $c P. Pitule, O. Vycital, J. Bruha, P. Novak, P. Hosek, V. Treska, I. Hlavata, P. Soucek, M. Kralickova, V. Liska,
520    9_
$a AIM: Colorectal cancer (CRC) is one of the most common malignant diseases. The aim of our study was to describe the expression status of 12 selected candidate genes, by comparing paired samples of healthy colon mucosa and tumour tissues and to correlate obtained data with clinical and pathological features, with the goal of revealing associations for individual gene expressions and tumour behaviour. MATERIALS AND METHODS: Samples from 53 patients with CRC were analyzed. Patients were divided into two groups based on the presence or absence of distant metastases at the time of primary tumour surgery. Expression levels were assessed by quantitative real-time polymerase chain reaction. RESULTS: We found changes in the expression of 10 out of 12 analyzed genes. Four genes were significantly up-regulated in tumour tissues: leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5; p<0.001), collagen triple helix repeat containing 1 (CTHRC1; p<0.001), visinin-like 1 (VSNL1; p<0.001) and versican (VCAN; p=0.001). Six genes were down-regulated: destrin (DSTN; p=0.004), mesoderm induction early response 1, family member 3 (MIER3; p<0.001), acyl-CoA synthetase long-chain family member 5 (ACSL5; p=0.002), mitogen-activated protein kinase 1/ERK (MAPK1; p<0.001), claudin 23 (CLDN23; p<0.001) and solute carrier family 26 (sulfate transporter), member 2 (SLC26A2; p<0.001). We recorded longer overall survival (OS) in the group of patients with higher expression of VSNL1 (p=0.032). Patients with more pronounced down-regulation of CLDN23 had shorter OS (p=0.045). In the group of patients without distant metastases, longer OS and disease-free interval (DFI) were found for patients with higher SLC26A2 expression in tumour tissues (p=0.036 and p=0.011, respectively). In the same group, lower expression of VSNL1 in healthy tissue corresponded to a longer DFI (p=0.020), smaller decrease of SLC26A2 and ACSL5 meant longer DFI (p=0.041 and p=0.040, respectively), as did greater increase of LGR5 expression (p=0.026). CONCLUSION: We identified differences in the expression of 10 genes in colorectal cancer tissue compared to healthy colon mucosa, and found prognostic significance for these changes which could be used for the development of a disease risk scoring system.
650    _2
$a senioři $7 D000368
650    _2
$a adjuvantní chemoterapie $7 D017024
650    _2
$a kolon $x metabolismus $x patologie $7 D003106
650    _2
$a kolorektální nádory $x farmakoterapie $x genetika $x mortalita $x patologie $7 D015179
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a paliativní péče $7 D010166
650    _2
$a prognóza $7 D011379
650    _2
$a messenger RNA $x genetika $7 D012333
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
650    _2
$a míra přežití $7 D015996
650    _2
$a nádorové biomarkery $x genetika $7 D014408
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Vyčítal, Ondřej, $d 1985- $7 mzk2016922773
700    1_
$a Brůha, Jan, $d 1984- $7 mzk2016922447
700    1_
$a Novák, Petr, $d 1968- $7 xx0079055
700    1_
$a Hošek, Petr $7 xx0224573
700    1_
$a Třeška, Vladislav, $u - $d 1957- $7 jn20000402436
700    1_
$a Hlavatá, Ivona $u - $7 _AN063454
700    1_
$a Souček, Pavel $u - $7 xx0060511
700    1_
$a Králíčková, Milena, $u - $d 1972- $7 xx0069996
700    1_
$a Liška, Václav, $u - $d 1978- $7 xx0073943
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 33, č. 11 (2013), s. 4855-4865
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24222123 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140401 $b ABA008
991    __
$a 20190710101846 $b ABA008
999    __
$a ok $b bmc $g 1017890 $s 849334
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 33 $c 11 $d 4855-4865 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
GRA    __
$a NT12025 $p MZ0
GRA    __
$a NT14329 $p MZ0
LZP    __
$a Pubmed-20140401

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...